Prescribing Trimbow®
Each dose contains three established molecules for the maintenance treatment of your adult patients with moderate to severe COPD not adequately treated with ICS/LABA or LABA/LAMA who require triple therapy1,2
Each metered dose contains:1,2
- 100 mcg beclometasone
- 6 mcg formoterol
- 10 mcg glycopyrronium
Each delivered dose contains:1,2


Trimbow contains beclometasone, formoterol and glycopyrronium in a solution or dry powder formulation resulting in an aerosol with extrafine particles.1,2
Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2
Trimbow pMDI 87/5/9 is licensed for use with an AeroChamber Plus® spacer[[1]]
As a pMDI, Trimbow 87/5/9 has the option to be used with an AeroChamber Plus® spacer.1
- Patients already familiar with a pMDI + spacer can use the same inhalation technique with Trimbow pMDI 87/5/91,4
- The option of using Trimbow pMDI 87/5/9 with an AeroChamber Plus® spacer can reduce oropharyngeal deposition and assist with hand-breath coordination1,5
Dose counter
Inclusion of a dose counter means patients can keep track of their remaining Trimbow doses at any time.1,2
NEXThaler device
Trimbow NEXThaler 88/5/9’s inhalation counter and audible ‘click’ can help to reassure patients that they have successfully inhaled their medication.2
Regardless of COPD severity, 100% of patients in an open-label, single-arm study had successful inhalation with a placebo NEXThaler. Patients with COPD aged ≥40 years. 72 patients were enrolled, with data analysed for 69 of the patients (mean FEV1 48.7% predicted [17–92%]).6
For additional information to share with your patients who have been prescribed Trimbow please visit our Trimbow patient and carer site.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.